Find a Physician | How to Contribute | About Us | Clinical Trials
 
Call 312-695-1102 with questions about Clinical Trials
Clinical Trials

Clinical Trial NRG BR003

Title
A Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel with or without Carboplatin for Node-Positive or High-Risk Node-Negative Triple-Negative Invasive Breast Cancer
Principal Investigator
William Gradishar
Details
  • Status: Accepting New Patients
  • Study Type: Therapeutic, Treatment
  • Protocol No:.NRG BR003
Purpose
The purpose of this study is to compare the good and bad effects of the chemotherapy drug, carboplatin, given with the usual chemotherapy drugs after surgery, compared to the usual chemotherapy drugs given without carboplatin.
Overview
This study will allow the researchers to know whether giving carboplatin with the usual chemotherapy is better, the same, or worse than giving the usual chemotherapy. If giving carboplatin with the usual chemotherapy drugs is better, there should be a higher chance that your breast cancer will not return. Carboplatin is FDA-approved for the treatment of cancer and is used for the treatment of breast cancer that has spread, but it has not yet been proven useful in earlier stages of breast cancer.
Eligibility
Some of the eligibility criteria include:
  • Participants must be 18 years of age or older.
  • Participants must have breast cancer that is HER2-negative and is not sensitive to hormone treatment.
  • Participant must have already been treated with surgery.
Note: This is only a partial list of eligibility criteria. Please contact the Lurie Cancer Center for complete screening information if you are interested in this clinical trial.
Description of Treatment
This study has two study groups. Group 1 will get the usual chemotherapy drugs used for this type of cancer: doxorubicin and cyclophosphamide, followed by paclitaxel.Group 2 will get the usual chemotherapy drugs used for this type of cancer: doxorubicin and cyclophosphamide, followed by paclitaxel plus the chemotherapy drug called carboplatin.
Contact
Clinical Trials Recruitment Nurse
Robert H. Lurie Comprehensive Cancer Center
312.695.1102
cancertrials@northwestern.edu

Find Related Clinical Trials

Browse by Disease Sites

Other Clinical Trials by William Gradishar

last updated: 19-Oct-17 07:34 AM

 

Clinical trial availability changes frequently. Please check this site often for updates or call 312.695.1102 for personal assistance.